Tevogen Logo Notified.png
Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference
December 23, 2024 09:38 ET | Tevogen Bio Inc
WARREN, N.J., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
fibrobiologics-logo-2022.jpg
FibroBiologics Announces $25 Million Financing
December 23, 2024 07:55 ET | Fibrobiologics, Inc.
HOUSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
OBI Logo.jpg
浩鼎、日本頂尖醣化學衍生技術公司 GlyTech簽署二協議
December 23, 2024 04:00 ET | OBI Pharma Inc.
台灣台北, Dec. 23, 2024 (GLOBE NEWSWIRE) -- 台灣浩鼎(4174.TWO)23日發布,與日本專注於聚醣生產和醣化學衍生技術的GlyTech, Inc.,簽署行銷和材料移轉兩項協議;日後將藉GlyTech之力,推廣日本生技製藥業採用浩鼎自主開發的GlycOBI® ADC (antibody-drug conjugate) 關鍵技術,以創造雙贏,雙方共享利益。 ...
OBI Logo.jpg
浩鼎、日本顶尖糖化学衍生技术公司 GlyTech 签署二协议
December 23, 2024 04:00 ET | OBI Pharma Inc.
台湾台北, Dec. 23, 2024 (GLOBE NEWSWIRE) -- 台湾浩鼎(4174.TWO)23日发布,与日本专注于聚糖生产和糖化学衍生技术的GlyTech, Inc.,签署行销和材料移转两项协议;日后将借GlyTech之力,推广日本生技制药业采用浩鼎自主开发的GlycOBI® ADC (antibody-drug conjugate) 关键技术,以创造双赢,双方共享利益。 ...
OBI Logo.jpg
OBI Pharma Enters Collaboration with GlyTech to Expand GlycOBI® Enabling Technologies Outreach in Japan and to Advance Glycan Production
December 23, 2024 04:00 ET | OBI Pharma Inc.
OBI Pharma collaborates with GlyTech to advance GlycOBI® technologies in Japan, enhancing glycan production and enabling novel ADC therapeutic innovations.
QuantumBioPharma-Logo-400x400.png
Quantum BioPharma Diversifies Treasury with the Purchase of USD $1,000,000 of Bitcoin (BTC) and Other Cryptocurrencies and to Allow for Future Financings and Other Transactions in Cryptocurrency
December 20, 2024 07:30 ET | Quantum BioPharma
TORONTO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce that after receiving approval...
Tevogen Logo Notified.png
Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda
December 19, 2024 08:30 ET | Tevogen Bio Inc
WARREN, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
Photys_Logo.jpg
Photys Therapeutics Announces Research Collaboration with Novo Nordisk to Develop Induced Proximity PHICS Technology for Cardiometabolic Diseases
December 18, 2024 07:30 ET | Photys Therapeutics, Incl
Photys and Novo Nordisk established a research collaboration to discover a new class of medicine for cardiometabolic diseases.
Vandria+Logo+-+CMYK+Color.png
Vandria announces first subjects dosed in its first-in-human Phase 1 clinical trial of VNA-318 brain-penetrant mitophagy inducer
December 18, 2024 03:00 ET | Vandria
LAUSANNE, Switzerland, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Vandria SA, a company at the vanguard of mitochondrial therapeutics developing first-in-class small molecule mitophagy inducers, today...
BHIANT Logo.png
BHIANT Celebrates Milestones in Workforce Development and Industry Collaboration, Sets Vision for 2025
December 17, 2024 10:00 ET | BHIANT
DALLAS, Dec. 17, 2024 (GLOBE NEWSWIRE) -- The Biotechnology and Healthcare Industry Alliance of North Texas (BHIANT) proudly announces significant progress in workforce development and industry...